A medical report published earlier this week says a boy in the U.K. developed erythema ab igne, or "toasted skin syndrome," after resting a laptop on his abdomen for up to eight hours a day, often while it was charging. "The marks were described as being in a patch about 15 centimeters (six inches) wide, made of flat, reddish-brown 'interlacing lines forming irregular circles and a lace-like morphology,'" reports Ars Technica. From the report: Based on the appearance, the doctors started reconsidering some sort of bruising and started asking him more questions. This is when he mentioned that he was homeschooled and used a laptop for his schoolwork. He said he typically did his work by resting his laptop on his abdomen while he worked, sometimes for up to eight hours a day, and often while the laptop was charging. Then they understood what it was. The doctors diagnosed the boy with erythema ab igne (EAI), which translates from Latin as "redness from fire" and is also sometimes called "toasted skin syndrome." This is a skin condition caused by repeated, prolonged exposure to low-grade heat -- heat not hot enough to cause actual burns. It's most often seen in adults, and common causes include using heating pads or hot water bottles for chronic pain or sitting too close to space heaters. Some people also develop it from certain occupational hazards, like glassblowing and metal work. EAI produces a lace-like rash, just like the boy's. It's unclear how EAI develops exactly. But researchers hypothesize that chronic heat exposure leads to damage to superficial blood vessels and the release of red blood cells, forming the tell-tale red reticulated pattern. While the boy's condition looked ominous, the good news is that EAI is generally benign and reversible -- once you remove the heat source. For severe or long-term conditions, some pigmentation and scarring can remain. But the boy's parents checked back in over several months, reporting that the rash faded and then completely resolved. Hopefully, he also got some sort of laptop stand.

Read more of this story at Slashdot.

A genetically modified pig kidney kept a 66-year-old man off dialysis for a record nine months, marking the longest survival yet for a pig kidney transplanted into a living person and the first time such an organ successfully served as a bridge to a later human transplant. The Guardian reports: Tim Andrews was seriously ill with end-stage kidney disease caused by type 2 diabetes and had only a 9% chance of receiving a human kidney within five years, against a more than 40% risk of dying or being removed from the waiting list. Kidney transplantation provides the best survival and quality of life for patients with end-stage kidney disease, but global demand for human organs far exceeds supply. Surgeons in the US successfully transplanted a kidney from Wilma, a Yucatan miniature pig, into Andrews, after genetically engineering it to be compatible with his immune system. The kidney kept Andrews free of dialysis for a record nine months, the longest period ever recorded, before it began failing and he received one from a dead human donor. It was also the first time a pig's kidney had been used as a temporary "bridge" to a human transplant. The breakthrough has been detailed in the journal Lancet.

Read more of this story at Slashdot.

CNN reports that "A one-time snip of a key gene lowered heart-clogging cholesterol by about 50% over an entire year with no adverse effects, scientists have reported." The overwhelmingly positive results were found in four people who had taken the highest dose of the experimental treatment during a pilot study published in The New England Journal of Medicine in November 2025. That study was extremely small — only 15 patients with dangerously high cholesterol that did not respond to medication. The research was designed to test the safety of five different doses of a gene-altering infusion delivered by CRISPR-Cas9, a biological scissor which cuts a targeted genetic location to modify or turn a gene on or off. "If you'd asked me 15 years ago if we could have done something like this, I would have thought you were crazy," senior study author Dr. Steven Nissen, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic in Ohio, told CNN previously. An update on the study, published Friday in NEJM, appears to answer a key question: Does the intervention last? "Is something like this truly a one and done? That was always the question," said lead study author Dr. Luke Laffin, a preventive cardiologist at Cleveland Clinic's Heart, Vascular & Thoracic Institute. "This new data is essentially saying that the decreases in LDL cholesterol and triglycerides we saw at 60 days after treatment have lasted over a year," Laffin said. "In people who took the highest dose, the reduction seems durable and safe...." If larger clinical trials show similar results, the procedure could be a game changer for young people with severe disease, preventive cardiologist Dr. Ann Marie Navar, an associate professor of cardiology at UT Southwestern Medical Center in Dallas, told CNN previously. "If you're 20 and you have really high cholesterol, it may make a lot more sense to have a one-time treatment that doesn't require you to have to take a pill every single day or shot every two weeks for the next 60 years," said Navar, who was not involved in the study. "The potential for this is just enormous." Being born with this mutation naturally "drastically lowers or even eliminates a person's risk for heart disease," the article points out. And the study's senior author adds "now that CRISPR is here, we have the ability to change other people's genes so they too can have this protection."

Read more of this story at Slashdot.

An anonymous reader quotes a report from The Guardian: A common sweetener used in products such as chewing gum, toothpaste, jam, yoghurts and ice-cream has been linked to an increased risk of strokes, heart attacks and death. Xylitol is a sugar alcohol present in some natural foods in very low amounts. It is also added -- often in amounts 1,000 times higher -- to artificially sweeten foods, beverages and oral care products. Despite its growing use, the long-term health impacts of xylitol have never been widely studied. In the largest study of its kind, researchers found high blood levels of xylitol were associated with an increased risk of major adverse cardiovascular events. The findings were presented in Munich at the European Society of Cardiology (ESC) annual congress, the world's largest heart conference. Researchers looked at 17,710 people and compared the 25% with the highest levels of xylitol in their blood against the 25% with the lowest. Those who had the highest amount were 57% more likely to die or suffer a heart attack or stroke, than those with the least, within six years. Even after 30 years, they were still 18% more likely to have suffered one of these cardiac events. Taken with data from the middle quartiles, the results from both cohorts suggested a dose-dependent relationship: the higher the xylitol blood levels, the higher the cardiovascular event rate. Furthermore, the researchers showed that there was consistent increase in cardiovascular events with xylitol irrespective of baseline characteristics, such as age and sex. The researchers also highlighted that the association was independent of underlying factors such as body mass index, hypertension, diabetes and lipid levels, which might predispose people to low-calorie products.

Read more of this story at Slashdot.

The FDA has authorized the first wearable in the U.S. to continuously monitor ketone levels and the first device globally to track both ketones and glucose together in a single system. From a report: [Abbott's] Libre Duo 10 Day continuously measures both glucose and ketone levels in the fluid just beneath the skin every minute, day and night. Readings are transmitted wirelessly to a compatible smartphone, where users can view current glucose and ketone levels and whether those values are trending up or down. The device also can send automatic alerts if ketone levels reach a concerning threshold. The FDA noted that ketone information should be interpreted in the context of glucose readings and symptoms. Ketones are produced when the body uses fat instead of glucose for energy. When ketone levels rise too high, patients with diabetes can develop diabetic ketoacidosis (DKA), a serious complication that can progress quickly and become life-threatening without prompt treatment. Until now, patients who needed ketone monitoring had to test separately using methods that provided a single measurement at one point in time. Those tests could not show whether ketone levels were rising or falling. For patients with diabetes -- particularly those at higher risk for DKA -- continuous glucose and ketone monitoring may provide earlier warning of metabolic deterioration and support timelier sick-day management, hydration, insulin adjustment, and escalation of care when clinically appropriate.

Read more of this story at Slashdot.

Moderna and Merck say their personalized mRNA melanoma vaccine significantly reduced both cancer recurrence and spread in a late-stage trial. The treatment could reach patients as soon as next year if regulators approve it. Reuters reports: Moderna developed the vaccine with Merck and tested it together with immunotherapy drug Keytruda, a widely used treatment for melanoma. [...] This is the first positive late-stage trial result for an mRNA cancer vaccine, which trains a patient's immune system to fight tumors by targeting specific mutations in those cells and the first such study to show that adding a treatment to Keytruda worked better than that therapy alone. Similar approaches are being tested against lung, breast and pancreatic cancers. [...] The cancer treatment combines Merck's Keytruda with a made-to-order mRNA vaccine from Moderna that is based on an analysis of mutations found in the patients' own tumors. The trial enrolled 1,137 high-risk patients with stage IIB-IV melanoma that had been surgically removed. Volunteers were randomized to receive up to nine doses of Keytruda plus the personalized vaccine or Keytruda alone for about one year. The companies said no new safety signals have emerged in the trial. In January, the companies announced results of a mid-stage trial of the treatment showing that it reduced the risk of recurrence or death by 49% after five years. Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, said the Moderna results could signal a new era for treating solid-tumor cancers. "The positive hit here leads us into truly this next phase in immunotherapy," Knudsen said. "This is an auspicious start -- this is where things begin." Moderna shares more than doubled on the news, adding about $30 billion to its market value.

Read more of this story at Slashdot.

A study of more than 64,000 people born around the end of Britain's postwar sugar rationing found that those exposed to less sugar during their first 1,000 days had lower rates of five cancers decades later, including roughly 69% lower liver cancer risk and 36% lower breast cancer risk. They also "showed signs of slower biological aging" and "continued to consume less sugar and had healthier diets overall," according to the authors of a new study published in The Conversation. From the report: After the second world war, sugar remained rationed in Britain for several years. But in September 1953, rationing ended and people started eating a lot more sugar. Consumption nearly doubled. This meant that children born just a few months apart had very different levels of sugar exposure both in the womb and during early childhood. For our study, we used data from over 64,000 people born in Britain between 1951 and 1956. Those born earlier spent a larger share of their first 1,000 days under sugar rationing, while those born later experienced progressively less of it. [...] What is most surprising, however, is not the cancer results or the biological markers of ageing. It's how early-life sugar exposure continued to affect people's diets even 50 years later. We found that people who experienced sugar rationing early in life still consumed less sugar in adulthood, around age 50. They also ate less overall, and their diets were healthier and more diverse. This suggests that the level of sweetness people are exposed to very early in life may shape their taste preferences for a long time.

Read more of this story at Slashdot.

An anonymous reader quotes a report from The Guardian: Miniature human organs and other tissues are to be grown from NHS patients' cells in a drive to improve medicine testing and reduce the number of animals used in drug development. Scientists will use the clumps of tissue to learn how diseases vary between patients, helping them identify which treatments are best for different people based on the particular pathology underlying their condition. The move marks a shift away from the traditional use of animals as models for human disease, towards what researchers believe will be more accurate and reliable tests based directly on human tissues. Researchers have been growing tiny clumps of human organs, known as organoids, for more than a decade. Tests show that pieces smaller than a millimeter can mirror key features of full-scale organs and tissues, including how they falter with disease and respond to drugs. Armed with organoids grown from diseased human tissues, scientists can investigate whether new drug candidates reverse pathological changes in all or a subset of patients, and quickly identify ineffective drugs early in the process. Historically, more than 90% of drugs that clear animal testing go on to fail in human trials, raising questions about the value of the tests. US and European medicines regulators now encourage other approaches if available. "It's going to have a major impact on the numbers of animals used and the way we develop new drugs in the future," said Matthias Zilbauer, a clinical professor of paediatric gastroenterology at the Cambridge Stem Cell Institute. "We're not saying there won't be any animal use in the near or foreseeable future, because there are still certain issues that cannot be tested in these new models, but the reduction is very real." "A lot of human diseases either do not occur in animals or occur in a different way because they're not human," added Zilbauer. "We want tests and models that can tell us which treatments work, and in what patients, and a mouse cannot tell us that."

Read more of this story at Slashdot.